Members of the CF New Frontiers Committee (CFNFC) engaged in a meeting with representatives from Vertex Pharmaceuticals on 16 September 2020. Representing South Africa on a national level, the CFNFC attendees consisted of doctors specializing in paediatric and adult...
CFNFC is the SACFA subcommittee tasked with facilitating access to affordable CF drugs for patients in South Africa, with an initial focus on CFTR modulators such as Trikafta. Over the past few months of research and legal consultation, the committee has formulated a...
The life expectancy of patients with cystic fibrosis (“CF”) has increased substantially over the past 20 years – this has been primarily due to successes in coordinated delivery of care, and advances in CF treatment. This treatment, however, only focuses on...
COVID-19 Portal
